Previsão

Comprar	0
Manter	0
Vender	1

Notícias Ir para o feed de notícias

Euroapi to mothball metamizole production in Frankfurt and cut workforce

Euroapi will mothball its production facility for the painkiller metamizole in Frankfurt-Höchst at the end of the year and reduce the number of employees on site from around 750 to under 700. The company is withdrawing from several active ingredients for price-competitiveness reasons and plans to stepwise exit 13 substances by 2027. Across Europe many active-ingredient productions have been shifted in favor of Asian suppliers, which is why France is providing state funds to modernize Euroapi sites. Policymakers and industry are now debating subsidy programs and procurement rules to strengthen supply security and local value creation in active-ingredient production. » Mais em faz.net

Dados financeiros da empresa

No último trimestre, EUROAPI registou receitas de € 355,97 mi e um ganho líquido de -€ 141,29 mi

(EUR)	junho de 2026	YoY
Receitas	355,97 mi	-
Ganho bruto	55,72 mi	-
Ganho líquido	-141,29 mi	-
EBITDA	83,77 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 96,93 mi
Número de ações	95,57 mi
Máximo/mínimo de 52 semanas	€ 3,11 - € 1,01
Dividendos	Não
Beta	0,98
PER (PE Ratio)	-0,25
PEG (PEG Ratio)	0,00
P/VC (PB Ratio)	0,17
P/V (PS Ratio)	0,10

Perfil da empresa

Euroapi SA entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Das Unternehmen wurde im Jahr 2021 gegründet und hat seinen Sitz in Paris, Frankreich.